Clinical Trials
1091
164 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1951
Terminated
59
5.4%
Recruiting
134
12.3%
Suspended
3
0.3%
Withdrawn
7
0.6%
Active, not recruiting
102
9.3%
Completed
565
51.8%
Unknown
159
14.6%
Enrolling By Invitation
8
0.7%
Not yet recruiting
54
5.0%
No approval data available
- Bioxodes has appointed three world-leading neurovascular experts to its Clinical Advisory Board as it prepares for a pivotal Phase 2b/3 trial of BIOX-101 for intracerebral hemorrhage treatment. - The company's adaptive trial design will include up to 500 patients with functional outcomes as the primary endpoint, potentially enabling accelerated approval after positive Phase 2b interim data. - BIOX-101 targets the deadliest form of stroke affecting up to 40% of stroke-related deaths, with fewer than 20% of survivors achieving functional independence after six months. - Bioxodes is raising €70 million in Series B funding to support the trial, manufacturing, and regulatory processes, with anticipated U.S. approval in late 2030 and EU approval in 2031.
- MindWalk Holdings Corp. announced B Cell Llama™, a new platform for discovering VHH nanobodies designed specifically for bispecific antibodies and CAR-T cell therapies. - A peer-reviewed study in ACS Biomacromolecules demonstrated that multivalent nanobody formats achieved 10-25 times greater potency than monovalent forms and could overcome therapeutic resistance. - The platform integrates AI-guided precision through LensAI™ technology across the entire discovery process, from target selection to multispecific construct evaluation. - VHH-nanoparticle complexes showed preferential internalization by immune memory cells, suggesting potential immune-priming effects beyond target neutralization.
- The CRITICS-II phase II trial evaluated three preoperative-only treatment strategies in 201 patients with resectable gastric cancer across 16 Dutch centers. - Chemotherapy followed by chemoradiotherapy achieved the highest 1-year event-free survival at 84%, compared to 68% for chemotherapy alone and 78% for chemoradiotherapy alone. - The study demonstrates that preoperative chemotherapy alone was insufficient, while total neoadjuvant therapy emerges as the preferred strategy for further development. - Results support omitting adjuvant treatment when effective preoperative regimens are used, potentially improving patient compliance and outcomes.
- The iMODERN trial, the largest global study to date using iFR technology in heart attack patients, found no significant difference in major outcomes between immediate and delayed treatment of additional narrowed arteries over three years. - The study enrolled 1,146 patients across 41 hospitals in 14 countries and was published in The New England Journal of Medicine, confirming both treatment approaches are equally safe and effective. - Complementary ILIAS ANOCA study results demonstrated that physiology-guided coronary function testing significantly improved angina symptoms and quality of life in patients with no obstructive coronary arteries. - These findings provide cardiologists with evidence-based flexibility to tailor treatment timing decisions for individual heart attack patients without compromising long-term outcomes.
- Two Phase 2b clinical trials led by LMU University Hospital Munich demonstrated that sutezolid and delpazolid, both oxazolidinone antibiotics, offer safer alternatives to linezolid for tuberculosis treatment with no cases of nerve damage or blood toxicity observed. - The SUDOCU and DECODE trials, conducted in South Africa and Tanzania, tested these drugs in combination with bedaquiline, delamanid, and moxifloxacin, marking the first studies to evaluate these specific four-drug combinations. - Delpazolid at 1200 mg once daily achieved optimal drug levels and was well tolerated over 16 weeks, while sutezolid showed strong antibacterial activity across all tested doses. - The findings, published in The Lancet Infectious Diseases, address the urgent need for safer TB treatments as linezolid's prolonged use frequently causes serious adverse events including anemia and optical neuropathy.
- Philikos has enrolled the first patient in a Phase 1/2 trial evaluating T-Guard for diffuse cutaneous systemic sclerosis (dcSSc), a severe autoimmune disorder with limited treatment options. - The open-label study will assess safety and preliminary efficacy in 12 early-stage dcSSc patients whose disease remains refractory despite prior immunosuppressive therapy. - T-Guard, administered as four infusions over one week, aims to provide a safer alternative to hematopoietic stem cell transplantation by selectively depleting disease-associated T cells and NK cells.
- Imec has developed a highly miniaturized ingestible sensor measuring just 2.1cm in length and 0.75cm in diameter, three times smaller than existing capsule endoscopies, capable of monitoring gut health for up to a week. - The innovative device is the first to measure redox balance, a marker for oxidative stress and inflammation, alongside pH and temperature throughout the entire gastrointestinal tract without requiring unpleasant bowel preparation. - Following successful testing in healthy volunteers, Imec plans to evaluate the sensor in patient populations with cancer and inflammatory disorders in collaboration with Radboud University Medical Center.
- Thiogenesis Therapeutics has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare inherited mitochondrial disease with no approved treatments in the EU or US. - The randomized, double-blind, placebo-controlled trial will enroll 12 patients across centers in the Netherlands and France, with endpoints including walking ability, fatigue severity, and quality of life. - TTI-0102 is a prodrug designed to increase intracellular levels of glutathione and taurine, both deficient in MELAS patients, potentially addressing the underlying oxidative stress contributing to the disease.
- Men with prostate cancer and the MMRd mutation experienced significantly extended progression-free survival with dual immunotherapy. - The disease control rate at six months in MMRd tumors was 81%, substantially higher than other mutation types. - Median progression-free survival in the MMRd group reached 32.7 months, a notable improvement compared to other groups. - These findings suggest that immunotherapy could be a beneficial treatment option for a subset of prostate cancer patients with specific genetic profiles.
- Google's life sciences division Verily collaborates with Radboud University Medical Center and ParkinsonNet to study disease progression in 650 Parkinson's patients using advanced imaging and wearable technology. - The study aims to understand individual variations in Parkinson's disease progression and treatment response, potentially enabling more personalized treatment approaches for the 10 million affected globally. - Researchers will utilize real-time data collection through advanced brain imaging, molecular analysis, and wearable devices, with findings to be made freely available to Dutch hospitals and international researchers.
